ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0712

ESKD Patients Hospitalized with COVID-19: Early Outcomes in Bronx, New York

Session Information

Category: Coronavirus (COVID-19)

  • No subcategory defined

Authors

  • Fisher, Molly, Montefiore Medical Center, Bronx, New York, United States
  • Yunes, Milagros, Montefiore Medical Center, Bronx, New York, United States
  • Mokrzycki, Michele H., Montefiore Medical Center, Bronx, New York, United States
  • Golestaneh, Ladan, Montefiore Medical Center, Bronx, New York, United States
  • Coco, Maria, Montefiore Medical Center, Bronx, New York, United States
Background

It is unclear whether end-stage kidney disease (ESKD) patients with COVID-19 are at increased risk for adverse outcomes due to impaired immune responses attributable to uremia. Alternatively, a weakened immune state could mitigate the cytokine surge observed in non-ESKD patients with COVID-19. The aim of our study is to describe the clinical characteristics and short term outcomes in ESKD patients requiring hospitalization for COVID-19.

Methods

We performed a retrospective study of 114 consecutive ESKD patients hospitalized at two major hospitals in the Bronx with COVID-19 from March 9, 2020 to April 12, 2020 in the midst of the coronavirus surge in New York City. Clinical and laboratory data were extracted from the medical record and short term outcomes were reported.

Results

The mean age was 63 years (range 30-87); 61.4% were men and 88.6% were Black or Hispanic. Most had hypertension (89.5%) and diabetes mellitus 66% and 30.7% were nursing home residents. Intensive care unit admission was required in 13(11.4%) patients and 17(14.9%) required mechanical ventilation. In-hospital mortality occurred in 23(20%) patients and was similar to mortality observed in non-ESKD patients. Mortality was 59% in those who required mechanical ventilation. At the time of data censoring, 47% had been discharged and 32% remained hospitalized. Initial procalcitonin, ferritin, lactate dehydrogenase and lymphocyte percentage were significantly higher in those who died.

Conclusion

Short term mortality in Bronx ESKD patients hospitalized with COVID-19 was similar to non-ESKD patients. Mechanical ventilation was associated with high mortality. Initial elevated inflammatory markers may be predictors of mortality in ESKD patients with COVID-19. To date, this is one of the largest studies describing outcomes in hospitalized ESKD patients with COVID-19. Further studies describing long-term outcomes in this population following COVID-19 are needed.